Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-34c antagomir is a synthetic, chemically modified antisense oligonucleotide designed to specifically inhibit the activity of microRNA-34c (miR-34c). In the context of Alzheimer's disease, miR-34c is often upregulated in the hippocampus, where it suppresses the expression of proteins critical for synaptic function and memory, such as Postsynaptic Density Protein 95 (PSD-95) and the mammalian target of rapamycin (mTOR). By binding to miR-34c, the antagomir prevents it from interacting with its target mRNAs, thereby restoring the levels of PSD-95 and mTOR and ameliorating cognitive deficits. It is primarily used as an experimental therapeutic agent in preclinical models of neurodegeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-34c antagomir.